TABLE 2.

Peptide-PMO conjugates

Name	Target	PMO end attached to peptide	Cross-linker	Base sequence (5′→3′)a
P150	c-myc	3′, 5′, and 3′ + 5′ KFFKFFKFFKC	SPDP	ACG TTG AGG GGC ATC GTC GC
P152	c-myc	3′, 5′, and 3′ + 5′ KFFKFFKFFKC	GMBS	ACG TTG AGG GGC ATC GTC GC
P173	c-myc	3′ KFFKFFKFFKC	SPDP	ACG TTG AGG GGC ATC GTC GC
P187	c-myc control	3′ KFFKFFKFFKC	GMBS	ACT GTG AGG GCG ATC GCT GC
3 + 5′KFC-lacI	lacI	3′, 5′, and 3′ + 5′ KFFKFFKFFKC	GMBS	TTC ACA TTC ACC ACC CTG AA
3 + 5′KFC-lacI-scr	lacI control	3′, 5′, and 3′ + 5′ KFFKFFKFFKC	GMBS	ATC CTC CCA ACT TCG ACA TA
3′KFC-lacI	lacI	3′ KFFKFFKFFKC	GMBS	TTC ACA T TC ACC ACC CTG AA
3′KFC9-lacI-scr	lacI control	3′ KFFKFFKFFKC	GMBS	ATC CTC CCA ACT TCG ACA TA
5′KFC-lacI	lacI	5′ KFFKFFKFFKC	GMBS	TTC ACA TTC ACC ACC CTG AA
5′KFC-lacI-scr	lacI control	5′ KFFKFFKFFKC	GMBS	ATC CTC CCA ACT TCG ACA TA
rTat-lacI	lacI	5′ CRRRQRRKKR	GMBS	TTC ACA TTC ACC ACC CTG AA
rTat-lacI-scr	lacI control	5′ CRRRQRRKKR	GMBS	ATC CTC CCA ACT TCG ACA TA

^aMismatched bases are underlined. The complement of the start codon is shown in boldface type.